These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 11595192)

  • 21. Atorvastatin inhibits the 5-lipoxygenase pathway and expression of CCL3 to alleviate atherosclerotic lesions in atherosclerotic ApoE knockout mice.
    Yang LX; Heng XH; Guo RW; Si YK; Qi F; Zhou XB
    J Cardiovasc Pharmacol; 2013 Aug; 62(2):205-11. PubMed ID: 23615158
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cholesterol lowering and the vessel wall: new insights and future perspectives.
    Stulc T; Ceska R
    Physiol Res; 2001; 50(5):461-71. PubMed ID: 11702850
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changing concepts of atherogenesis.
    Libby P
    J Intern Med; 2000 Mar; 247(3):349-58. PubMed ID: 10762452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study.
    Kinlay S; Schwartz GG; Olsson AG; Rifai N; Sasiela WJ; Szarek M; Ganz P; Libby P;
    Circulation; 2004 Jul; 110(4):386-91. PubMed ID: 15262833
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanisms of acute coronary syndromes and the potential role of statins.
    Dupuis J
    Atheroscler Suppl; 2001 Feb; 2(1):9-14. PubMed ID: 11286155
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stabilization of atherosclerotic plaque during lipid lowering.
    Müller-Wieland D; Kotzka J; Krone W
    Curr Opin Lipidol; 1997 Dec; 8(6):348-53. PubMed ID: 9412775
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biological mechanisms for the clinical success of lipid-lowering in coronary artery disease and the use of surrogate end-points.
    Kinlay S; Selwyn AP; Delagrange D; Creager MA; Libby P; Ganz P
    Curr Opin Lipidol; 1996 Dec; 7(6):389-97. PubMed ID: 9117144
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rationale and design of a randomized clinical study to investigate the effect of ezetimibe, a cholesterol absorption inhibitor, on the regression of intracoronary plaque evaluated by non-obstructive angioscopy and ultrasound: The ZIPANGU study.
    Hiro T; Hirayama A; Ueda Y; Komatsu S; Matsuoka H; Takayama T; Ishihara M; Hayashi T; Saito S; Kodama K;
    J Cardiol; 2014 Dec; 64(6):501-7. PubMed ID: 24725763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The influence of low-dose atorvastatin on lipid levels and endothelial vascular function in patients with significant coronary artery stenosis.
    Kuryata OV; Yegorova YV
    Kardiol Pol; 2006 Jan; 64(1):44-8; discussion 49-50. PubMed ID: 16444629
    [TBL] [Abstract][Full Text] [Related]  

  • 30. More intensive lipid lowering is associated with regression of coronary atherosclerosis in diabetic patients with acute coronary syndrome--sub-analysis of JAPAN-ACS study.
    Arai H; Hiro T; Kimura T; Morimoto T; Miyauchi K; Nakagawa Y; Yamagishi M; Ozaki Y; Kimura K; Saito S; Yamaguchi T; Daida H; Matsuzaki M;
    J Atheroscler Thromb; 2010 Oct; 17(10):1096-107. PubMed ID: 20675955
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systemic cause of unstable atherosclerotic plaques. Atorvastatin and Thrombogenicity of Carotid Atherosclerotic Plaque (ATROCAP) study group.
    Cortellaro M; Cofrancesco E; Arbustini E; Gabrielli L; Tremoli E
    Lancet; 2000 Apr; 355(9212):1362-3; author reply 1363-4. PubMed ID: 10776765
    [No Abstract]   [Full Text] [Related]  

  • 32. [Atherosclerosis].
    Koga T; Sasaki J
    Nihon Rinsho; 1999 Jul; 57(7):1614-9. PubMed ID: 10429466
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Raman spectroscopic evaluation of the effects of diet and lipid-lowering therapy on atherosclerotic plaque development in mice.
    van De Poll SW; Römer TJ; Volger OL; Delsing DJ; Bakker Schut TC; Princen HM; Havekes LM; Jukema JW; van Der Laarse A; Puppels GJ
    Arterioscler Thromb Vasc Biol; 2001 Oct; 21(10):1630-5. PubMed ID: 11597937
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical study of the month. REVERAL and PROVE-IT: confirmation of the concept " the lower, the better" for cholesterol therapy in patients with coronary heart disease].
    Scheen AJ; Kulbertus H
    Rev Med Liege; 2004 Mar; 59(3):167-73. PubMed ID: 15139406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lipid lowering therapy and stabilization of atherosclerotic plaques.
    Krone W; Müller-Wieland D
    Thromb Haemost; 1999 Sep; 82 Suppl 1():60-1. PubMed ID: 10695487
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The relation between extent of coronary artery disease measured by quantitative coronary angiography and changes in lipid profile: insights from trials of atherosclerosis regression.
    Brener SJ; Ivanc TB; Hu T
    J Invasive Cardiol; 2008 Jun; 20(6):261-5. PubMed ID: 18523316
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibitory effect of co-administration of atorvastatin and endothelin-1 receptor antagonist on the progression of atherosclerosis in rabbit.
    Sun Y; Liu J; Yang B; Sai X; Li T; Wang D; Zhou R
    APMIS; 2014 Jun; 122(6):556-64. PubMed ID: 24164644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of atorvastatin 5 and 20 mg/d for reducing F-18 fluorodeoxyglucose uptake in atherosclerotic plaques on positron emission tomography/computed tomography: a randomized, investigator-blinded, open-label, 6-month study in Japanese adults scheduled for percutaneous coronary intervention.
    Ishii H; Nishio M; Takahashi H; Aoyama T; Tanaka M; Toriyama T; Tamaki T; Yoshikawa D; Hayashi M; Amano T; Matsubara T; Murohara T
    Clin Ther; 2010 Dec; 32(14):2337-47. PubMed ID: 21353104
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aggressive LDL-cholesterol lowering with atorvastatin results in regression of atherosclerosis.
    Cardiovasc J S Afr; 2001; 12(1):56. PubMed ID: 11474689
    [No Abstract]   [Full Text] [Related]  

  • 40. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization.
    Aikawa M; Rabkin E; Okada Y; Voglic SJ; Clinton SK; Brinckerhoff CE; Sukhova GK; Libby P
    Circulation; 1998 Jun; 97(24):2433-44. PubMed ID: 9641696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.